Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jean-Paul Kress
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Beta
- 1.78
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.26
Financials
Net Income
$-62.81MEBITDA
$-47.82MFree Cash Flow
$-25.79MEPS (diluted)
$-1.16Shares Outstanding (diluted)
54.30M+964455.2%Operating Expenses
$47.85MCash & Debt
$466.13MReturn of Capital
$4.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-695.98M | $-70.50 |
| 2024 | $0.00 | $-116.91M | $-34.00 |
| 2023 | $0.00 | $-117.86M | $-35.00 |
| 2022 | $0.00 | $-92.09M | $-46.60 |
| 2021 | $0.00 | $-68.90M | $-37.80 |
| 2020 | $0.00 | $-43.34M | $-26.60 |
| 2019 | $0.00 | $-10.84M | $-6.20 |
| 2018 | $0.00 | $-4.15M | $-14.60 |
Valuation
VORhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
145+107.14%Social Signal Score
Mentions (4)
- Newsreuters.com·5h ago·Negative
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
View source ↗ - Newsglobenewswire.com·6h ago·Positive
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p
View source ↗ - Newsglobenewswire.com·23d ago·Neutral
… with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores ≥11 achieved MSE BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), evaluating telitacicept in adults with generalized myasthenia gravis (gMG).
View source ↗ - Newsseekingalpha.com·43d ago·Positive
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗
Earnings
Thu, Nov 12(in 3 weeks)
Consensus estimate $-0.82 per share
Typical surprise -68.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-1.16 vs $-0.69miss
- Wed, May 13$-0.73 vs $-0.75beat
- Mon, Mar 30$44.50 vs $-1.14beat
- Thu, Nov 13$-121.63 vs $-3.06miss
- Tue, Aug 12$-251.20 vs $-11.40miss
- Thu, May 15$-5.20 vs $-5.00miss
Estimates and results for VOR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VOR officers and directors.
- Bought
- —
- Sold
- $98.4m
0 trades
69 trades
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
- Ra Capital Management, L.p.sold
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VOR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.